Literature DB >> 15120955

In vitro antimicrobial activity of orbifloxacin against Staphylococcus intermedius isolates from canine skin and ear infections.

Jean-Pierre Ganière1, Christine Médaille, Florence Etoré.   

Abstract

The objective of the study was to evaluate the in vitro activity of orbifloxacin against Staphylococcus intermedius strains isolated in France from canine skin and ear infections. The minimum inhibitory concentrations (MICs) of orbifloxacin against 240 field S. intermedius isolates (69 skin and 171 ear isolates) ranged from 0.016 to 8 mg l(-1), with MIC50 and MIC90 equal to 0.5 and 1 mg l(-1), respectively. Only one strain, a pyoderma isolate was resistant (MIC=8 mg l(-1)). Orbifloxacin was tested at different concentrations for killing rate against five isolates obtained from pyoderma cases and against a reference strain (Staphylococcus aureus ATCC 29213). Orbifloxacin expressed a concentration-dependent bactericidal activity against the S. aureus reference strain, but a time-dependent bactericidal activity against S. intermedius. Orbifloxacin induced bactericidal effect against the S. intermedius strains tested with concentrations equal to or two times MIC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15120955     DOI: 10.1016/j.rvsc.2004.02.002

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  3 in total

1.  Integration of pharmacokinetic and pharmacodynamic indices of orbifloxacin in beagle dogs after a single intravenous and intramuscular administration.

Authors:  Elias Gebru; Joong-Su Lee; Zhi-Qiang Chang; Mi-Hyun Hwang; Henrique Cheng; Seung-Chun Park
Journal:  Antimicrob Agents Chemother       Date:  2009-04-27       Impact factor: 5.191

2.  Post-antibiotic effect of orbifloxacin against Escherichia coli and Pseudomonas aeruginosa isolates from dogs.

Authors:  Kazuki Harada; Takae Shimizu; Yasushi Kataoka; Toshio Takahashi
Journal:  Acta Vet Scand       Date:  2012-03-20       Impact factor: 1.695

3.  Development and validation of a microbiological agar assay for determination of orbifloxacin in pharmaceutical preparations.

Authors:  Edith C L Cazedey; Hérida R N Salgado
Journal:  Pharmaceutics       Date:  2011-08-29       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.